3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Polycystic Ovary Syndrome
5
Neoplasms
3
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Posterior Fossa Ependymal Tumor
1
Ovarian Neoplasms
1
Obesity
1
Neoplasms by Site
1
Metabolic Diseases
1
Insulin Resistance
1
Infertility
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Drug-drug Interaction,SHR3680
1
Diabetes Mellitus, Type 2
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Breast Diseases
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
9
Cetuximab
5
Surveys and Questionnaires
4
Cisplatin
4
dostarlimab
2
abemaciclib
2
Standard of Care
2
Docetaxel
2
Carboplatin
2
130-nm albumin-bound paclitaxel
2
ulixertinib
1
trastuzumab deruxtecan
1
toripalimab
1
tislelizumab
1
tipifarnib
1
ribociclib
1
repotrectinib
1
patritumab deruxtecan
1
palbociclib
1
olaparib
1
nimotuzumab
1
monalizumab
1
ibrutinib
1
fludarabine
1
exemestane
1
entrectinib
1
ebselen
1
durvalumab
1
disitamab vedotin
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Metformin
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled